The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Adverse Events (AEs)
Timeframe: Up to 6 Months
Time to onset of serious adverse events (SAEs)
Timeframe: Up to 6 Months
Time to onset of AEs
Timeframe: Up to 6 Months
Time to resolution of AEs
Timeframe: Up to 6 Months
Time to resolution of SAEs
Timeframe: Up to 6 Months
Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade - Non-serious AE
Timeframe: Up to 6 Months
Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade - SAE
Timeframe: Up to 6 Months
Incidence of AEs leading to interruption of treatment
Timeframe: Up to 6 Months
Incidence of SAEs leading to interruption of treatment
Timeframe: Up to 6 Months
Incidence of AEs leading to treatment discontinuation
Timeframe: Up to 6 Months
Incidence of SAEs leading to treatment discontinuation
Timeframe: Up to 6 Months
Outcome of reported AEs
Timeframe: Up to 6 Months
Outcome of reported SAEs
Timeframe: Up to 6 Months
Number of participants with Yervoy and Opdivo treatment related adverse events as assessed by physician causality
Timeframe: Up to 6 Months
Number of participants with Yervoy and Opdivo treatment unrelated adverse events as assessed by physician causality
Timeframe: Up to 6 Months